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ABSTRACT
There is preliminary evidence that implantation of primary fetal striatal cells provides functional
beneﬁt in patients with Huntington’s disease, a neurodegenerative condition resulting in loss of
medium-sized spiny neurons (MSN) of the striatum. Scarcity of primary fetal tissue means it is
important to identify a renewable source of cells from which to derive donor MSNs. Embryonic stem
(ES) cells, which predominantly default to telencephalic-like precursors in chemically deﬁned
medium (CDM), offer a potentially inexhaustible supply of cells capable of generating the desired
neurons. Using an ES cell line, with the forebrain marker FoxG1 tagged to the LacZ reporter, we
assessed effects of known developmental factors on the yield of forebrain-like precursor cells in
CDM suspension culture. Addition of FGF2, but not DKK1, increased the proportion of FoxG1-
expressing cells at day 8 of neural induction. Oct4 was expressed at day 8, but was undetectable by
day 16. Differentiation of day 16 precursors generated GABA-expressing neurons, with few
DARPP32 positive MSNs. Transplantation of day 8 precursor cells into quinolinic acid-lesioned striata
resulted in generation of teratomas. However, transplantation of day 16 precursors yielded grafts
expressing neuronal markers including NeuN, calbindin and parvalbumin, but no DARPP32 6 weeks
post-transplantation. Manipulation of fate of ES cells requires optimization of both concentration
and timing of addition of factors to culture systems to generate the desired phenotypes.
Furthermore, we highlight the value of increasing the precursor phase of ES cell suspension culture
when directing differentiation toward forebrain fate, so as to dramatically reduce the risk of
teratoma formation.
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Introduction
Huntington’s disease (HD) is an inherited autosomal
dominant disorder characterized by progressive neu-
rodegeneration including extensive atrophy of dopa-
mine and cyclic adenosine 30, 50-monophosphate-
regulated phosphoprotein, 32kDa (DARPP32) posi-
tive striatal medium-sized spiny projection neurons
(MSNs) which leads to motor, cognitive and psychiat-
ric disturbances. There is currently no known cure for
HD and only limited symptomatic treatments are
available. Cell replacement by transplantation is one
therapeutic strategy being explored. The current ‘gold
standard’ for transplantation in HD utilizes primary
fetal whole ganglionic eminence; the site of MSN gen-
esis.1,2 However, the use of fetal tissue brings with it
logistical and ethical issues; in particular fetal tissue is
a scarce resource. Thus, there is a need for a renewable
source of donor cells, with pluripotent stem cells offer-
ing an attractive, potential alternative.3
Embryonic stem (ES) cells have the capacity for
unlimited self-renewal and proliferation, and are plu-
ripotent, with the capability to generate any cell type
from the 3 germ layers.4,5 These characteristics make
ES cells an attractive source of cells for use in cell-
replacement strategies. The main challenge with the
use of any renewable donor cell source is to generate
the speciﬁc phenotype required; for HD, striatal
MSNs.6 In addition, it may be necessary to eliminate
proliferative cells from pluripotent cultures (such as
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undifferentiated ES cells or proliferative precursors)
that may produce neurological damage through con-
tinued proliferation in the graft.
It is well documented that, following withdrawal of
serum and leukemia inhibitory factor (LIF), mouse ES
cells cultured in free-ﬂoating suspension under
deﬁned conditions without addition of exogenous fac-
tors, generate a proportion of neural precursor
cells.7,8,9 Different protocols yield varying percentages
of neural precursors (ranging from 60-90%), as indi-
cated by expression of Nestin and Sox1.8,9,10,11,12 Neu-
ral induction of mouse ES cells is enhanced by
addition of growth factors such as ﬁbroblast growth
factor-2 (FGF2), which induces an increase in Nestin,8
Sox19 and FoxG1 expression.10 In most reports analy-
sis has been performed following up to 8 d in culture.
Inhibition of Wnt signaling is reported to be necessary
for telencephalic generation during neural develop-
ment.13 Addition of the Wnt inhibitor Dickkopf-1
(DKK1) has been shown to increase the proportion of
FoxG1-expressing cells, if added to cultures between
days 0–5, but not later,11 indicating the importance of
timing for addition of factors for induction of speciﬁc
markers.
Neural induction protocols for ES cells have not
resulted in exclusively neural differentiation and the
resulting population is often heterogeneous, con-
taining multiple cell types.10,14,15 Speciﬁcally, deriva-
tion of striatal-like neurons, as evaluated with
markers such as gamma-amino butyric acid
(GABA), glutamate decarboxylase and DARPP32,
has been achieved following differentiation of mouse
ES cells, albeit in small numbers.16-19 However, the
continued presence of undifferentiated ES cells in
the neural induction culture system makes this cell
source less appealing for use in cell-replacement
therapies because of the potential to form teratomas.
Indeed uncontrolled proliferation has been observed
in several studies following transplantation of
neurally differentiated mouse and human ES cells.19-
23 In addition, it has been shown that the greater
the proportion of dividing cells (determined by bro-
modeoxyuridine (BrdU) immuno-reactivity) and
neural precursors (determined by Nestin immuno-
reactivity) within the transplanted population, the
greater the potential to generate tumors.20
One strategy to reduce the risk of teratoma forma-
tion would be to prolong the length of time ES cell-
derived precursors spend in neural induction culture
prior to transplantation, so that they may be more
completely differentiated with accompanying down-
regulation of pluripotent markers. Neural induction of
mouse ES cells using the suspension method has, to
date, been described after short periods of culture
only, and analysis of precursors beyond 8-10 d has not
been reported.
In this study, which follows on from previous
work from our group,10,15 we use a mouse ES cell
line where most of the FoxG1 coding sequence was
replaced with the LacZ reporter gene and expression
of the b-galactosidase (b-Gal) enzyme is under the
control of the FoxG1 promoter.24 FoxG1 is the earli-
est and most speciﬁc determinant of telencephalic
fate.25,26 Neural induction in chemically deﬁned
Figure 1. X-Gal expression in FoxG1Z-derived precursors. Within cultures there were cells present exhibiting no X-Gal expression (pink),
interspersed with X-Gal positive cells (blue) (A). Undifferentiated FoxG1Z ES cells (B) and precursors derived from a non-LacZ reporter ES
cell line (C) exhibited no X-Gal positive cells. X-Gal positive cells were counted at days 0, 2, 4, 6 and 8 of neural induction and are repre-
sented as a percentage of total eosin stained cells (D). Each bar on the graph represents a mean of 3 different cultures and error bars
represent SEM. There were signiﬁcantly more X-Gal positive cells with increasing time in culture. Signiﬁcant post-hoc differences are
indicated with brackets; p < 0.001. Scale bars D 50 mm
e1127311-2 S. V. PRECIOUS ET AL.
medium (CDM) suspension culture with and with-
out the addition of growth factors was assessed at
day 8 with analysis of expression of regional neural
precursor markers. Cultures were compared at day
8 and day 16 for expression of markers of ES cells
and neural precursor cells, and subsequently, neuro-
nal markers, following neuronal differentiation. Fur-
ther characterization of the mature differentiated
phenotype from neural precursors was assessed fol-
lowing transplantation into the rat quinolinic acid
(QA)-lesioned striatum, in particular looking for
differentiation toward striatal neuronal phenotypes.
Results
Forebrain-like character of ES cell-derived precursors
The use of the FoxG1Z mouse ES cell line in this
study enabled detection of FoxG1-positive cells fol-
lowing incubation with X-Gal, which yields a blue
product. FoxG1Z cells were cultured in CDM alone
and analyzed at different time points up to day 8.
Within cultures there was a mix of cells that were
positive or negative for X-Gal (Fig. 1A).
Undifferentiated FoxG1Z ES cells were negative for
X-Gal, as were precursors derived from a mouse ES
cell line without the LacZ reporter (CGR8.8)
(Figs. 1B, 1C). Counts of X-Gal positive cells
revealed a signiﬁcant increase in the proportion of
forebrain cells with increasing time in culture (F4,15
D 117.31, p < 0.001) (Fig. 1D). There were no X-
Gal positive cells identiﬁed at day 0 and the greatest
proportion of X-Gal positive cells was seen at day 8
(25.91 § 1.78%).
Effect of addition of FGF2 and DKK1 on FoxG1
expression
We have previously shown, and validated using
multiple mouse ES cell lines (E14, CGR8.8 and
IMT11), that addition of FGF2 to CDM neural
induction cultures results in increased expression of
FoxG1 and Nestin.10,15 Here, we found that addition
of increasing concentrations of FGF2 to CDM neu-
ral induction cultures on day 4 resulted in a signiﬁ-
cant increase in the percentage of X-Gal positive
cells at day 8 (F4,15 D 5.57, p < 0.05) (Fig. 2A).
Figure 2. Effect of addition of FGF2 and DKK1 on the proportion of forebrain cells. FoxG1Z cells were cultured in neural induction
medium with or without the addition of other factors. FGF2 (1, 5, 10 and 20 ng/ml) was added at day 4 and cultures were analyzed at
day 8 (A). Addition of 20 ng/ml FGF2 was initiated on either day 0, 2 or 4, and maintained through to analysis at day 8 (B). DKK1 (10,
100, 1000 ng/ml) was added at day 4 and cultures were analyzed at day 8 (C). Addition of 1000 ng/ml DKK1 was initiated on either day
0, 2 or 4 and maintained through to analysis at day 8 (D). Untreated or DKK1 treated (1000 ng/ml) precursors from day 4 to day 8 were
analyzed for expression of Axin using semi-quantitative RT-PCR (E). Cultures treated with 20 ng/ml FGF2 alone or both 20 ng/ml FGF2
and 1000 ng/ml DKK1 have signiﬁcantly more X-Gal positive cells than untreated cultures and those treated with 1000 ng/ml DKK1
alone (F). X-Gal positive cells were counted and are represented as a percentage of total eosin stained cells. Photomicrographs showing
X-Gal (blue) and eosin (pink) counterstaining at day 8 of neural induction, in untreated cultures (G); cultures treated with 20 ng/ml FGF2
at day 4 (H); cultures treated with 1000 ng/ml DKK1 at day 4 (I); and cultures treated with 20 ng/ml FGF2 and 1000 ng/ml DKK1 at day
4 (J). Each bar on the graphs represents a mean of 3 different neural induction cultures and error bars represent SEM. Signiﬁcant post-
hoc differences are indicated with brackets. (p < 0.05, p < 0.01, p < 0.001). Scale bars D 100 mm
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There was no signiﬁcant difference between cultures
receiving 1, 5 and 10 ng/ml FGF2, but those receiv-
ing 20 ng/ml FGF2 yielded a signiﬁcantly higher
proportion of X-Gal positive cells. When addition of
20 ng/ml FGF2 was initiated on different days (day
0, 2 or 4) and maintained through to analysis at day
8, the percentage of X-Gal positive cells was signiﬁ-
cantly increased the later the initial addition (F3,12
D 33.89, p < 0.05) (Fig. 2B).
Next we wanted to target a different pathway and
determine the effects of Wnt inhibition on the FoxG1
population. Addition of increasing concentrations of
the Wnt inhibitor DKK1 to CDM neural induction
cultures on day 4 did not result in a signiﬁcant differ-
ence in the percentage of X-Gal positive cells (F3,12 D
3.45, p D n.s) (Fig. 2C). The lack of effect of 1000 ng/
ml DKK1 was not modiﬁed by altering the day of
treatment initiation (day 0, 2 or 4; F3,11 D 2.19 p D n.
s) (Fig. 2D). The integrity of the Wnt-signaling path-
way was conﬁrmed by the reduced expression of the
pathway component Axin following addition of the
top dose of DKK1, when compared to untreated cul-
tures (t2 D 19.54, p < 0.01) (Fig. 2E).
The initial aim here was to determine the optimum
concentrations of FGF2 and DKK1 for maximum
expression of FoxG1, and then to add them in combi-
nation to determine if a further increase in FoxG1
expression would ensue. The effect of DKK1 was ini-
tially analyzed in the absence of FGF2. To determine
if there was an additive effect of these 2 factors, 20 ng/
ml FGF2 was added in conjunction with 1000 ng/ml
DKK1 at day 4 for analysis at day 8 (Figs. 2F-J). There
was a highly signiﬁcant overall effect of treatment
(F3,12D 114.60, p < 0.001) (Fig. 2F). Cultures treated
with both 20 ng/ml FGF2 and 1000 ng/ml DKK1, or
with 20 ng/ml FGF2 alone, generated signiﬁcantly
higher numbers of X-Gal cells compared to untreated
cultures and cultures treated with DKK1 alone. How-
ever, there was no difference between cultures treated
with FGF2 alone and those that also received DKK1.
In vitro characterization of FoxG1Z-derived
precursors
Expression of Oct4 (Figs. 3A, 3B) and Nestin
(Figs. 3C, 3D) were assessed in ES cell-derived precur-
sors in neural induction culture at day 8 and day 16.
Oct4 expression signiﬁcantly decreased over time F8,27
D 115.81, p < 0.001) (Fig. 3E). Notably, expression
Figure 3. In vitro comparison of day 8 and day 16 FoxG1Z-
derived precursors. FoxG1Z precursors were plated onto sub-
strate at day 8 (A, C) and day 16 (B, D). Cultures were ﬁxed
after 4 hours and immuno-labeled with Oct4 (red) (A, B and
E) or Nestin (red) (C, D and F) and Hoechst nuclear stain
(blue). At day 8 few Oct4 positive cells were present (A) and
at day 16 there were no Oct4 positive cells detected (B). The
neural precursor marker Nestin was more highly expressed in
precursors at day 8 (C) compared with day 16 (D). Oct4 and
Nestin immuno-positive cells were counted and are repre-
sented as a percentage of total Hoechst cells (E and F,
respectively). Each bar on the graphs represents a mean of 3
different neural induction cultures and error bars represent
SEM. (p < 0.001). Scale bars D 100mm (A and B) and 50
mm (C and D)
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decreased from 2% at day 8 to 0% at day 16. Nestin
expression decreased signiﬁcantly between day 8 and
day 16 (t4 D 8.67, p<0.001) (Fig. 3F).
Expression of dorso-ventral markers Pax6, Nkx2.1
and Mash1 was analyzed, comparing precursors at day 8
and day 16 (Figs. 4A-I). There was no signiﬁcant differ-
ence in Pax6 expression (t5D 0.38, p D n.s) (Figs. 4A-C)
or Nkx2.1 expression (t4D 1.075, p D n.s) (Figs. 4D-F)
between these 2 time points. Mash1 expression was sig-
niﬁcantly different, with more immune-positive cells at
day 16 (12.66 § 0.82%) compared with day 8 (2.26 §
0.56%) (t4D 10.55, p< 0.001) (Figs. 4G-I).
The next step was to evaluate neuronal differenti-
ation; FoxG1Z precursors were plated onto sub-
strate in neuronal differentiation medium and
differentiated for 7 d Following differentiation
FoxG1Z cells continued to express b-Gal and there
was co-expression with the neuronal marker b-III-
tubulin. Day 16 precursors yielded a comparable
proportion of neurons (30.71 § 4.89%) and a
greater proportion of GFAP immune-positive cells
(14.92 § 1.48%) compared with day 8 precursors
(data not shown).
Assessment of neuronal phenotype following 7 d
in neuronal differentiation medium revealed the
presence of GABAergic neurons, from both day 8
and day 16 cultures (Figs. 5A-D; 5E-H, respec-
tively). DARPP32 was never detected in day 8 dif-
ferentiated cultures but was found to be expressed
at low levels at day 16 (4.16 § 1.77%, as a percent-
age of b-III-tubulin positive cells) (Figs. 5I-L). The
same was seen with FoxP1, where no expression
Figure 4. Dorso-ventral comparison of day 8 and day 16 FoxG1Z-derived precursors. FoxG1Z precursors were plated onto substrate at
day 8 (A, D, G) and day 16 (B, E, H). Cultures were ﬁxed after 4 hours and immuno-labeled with Pax6 (red) (A and B), Nkx2.1 (red) (D and
E) or Mash1 (red) (G and H) and Hoechst nuclear stain (blue). Pax6, Nkx2.1 and Mash1 immuno-positive cells were counted and are rep-
resented as a percentage of total Hoechst cells (C, F and I, respectively). There was no signiﬁcant difference in expression of Pax6 and
Nkx2.1 between day 8 and day 16. There were signiﬁcantly more Mash1 immuno-positive cells at day 16 than at day 8. Each bar on the
graphs represents a mean of 3 different neural induction cultures and error bars represent SEM. (p < 0.001). Scale bars D 50 mm.
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was evident at day 8, but by day 16 FoxP1 expres-
sion was detected (16.89 § 0.81%, as a percentage
of total Hoechst positive cells). Additionally, there
were a small number of cells that co-expressed
FoxP1 and DARPP32 (Figs. 5M-P).
Graft survival and differentiation
FoxG1Z precursors generated following neural
induction in CDM with addition of FGF2 at day 4
were transplanted at either day 8 or day 16 into
the QA-lesioned rat striatum. Day 8 grafts at 2
weeks post-transplantation had the appearance of
uncontrolled proliferation. There were graft masses
with well-deﬁned borders, ﬁlling the striatum of
the grafted side, and pushing into the cortex
(Fig. 6A). All grafts in this group were similar in
appearance, with ‘swirling’ patches of tissue
throughout, based on Nissl staining. In comparison,
all animals in the day 16 graft group survived for
analysis at 6 weeks post-transplantation. Nissl-
stained sections revealed the presence of cell-dense
regions throughout the graft, with less well-deﬁned
borders than the day 8 grafts, suggesting a degree
of integration of the day 16 grafts into the host
brain, rather than the distinctly isolated cell mass
of the day 8 grafts (Fig. 6B). Additionally, day 16
grafts exhibited less heterogeneous appearance than
day 8 grafts.
Graft volumes were based on analysis of b-Gal
immunoreactivity (Fig. 6C) of FoxG1-positive cells:
mean graft volume for day 8 grafts was 336.32 §
Figure 5. In vitro neuronal differentiation of FoxG1Z-derived precursors. FoxG1Z precursors were plated onto substrate at day 8 (A-D)
and day 16 (E-P) and differentiated for 7 d in neuronal differentiation medium with no additional growth factors. Cultures were triple-
labeled for b-III-tubulin (red) and GABA (green) at day 8 (A-D) and day 16 (E-H); b-III-tubulin (green) and DARPP32 (red) (I-L); and FoxP1
(green) and DARPP32 (red) (M-P); with Hoechst nuclear stain (blue). D, H, L and P represent merged images of the ﬁrst 3 photomicro-
graphs in each row. Scale bars D 100 mm (D) and 50 mm (H, L and P).
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129.16 mm3, with a wide range between animals
(19.24 to 962.32 mm3); and mean graft volume for
day 16 grafts was 21.87 § 4.63mm3, with a range from
13.14 to 56.5 mm3.
Day 16 grafts were analyzed for co-expression
of b-Gal with markers to demonstrate the neural
lineage of graft-derived cells. b-Gal immune-posi-
tive cells were seen to double-label with NeuN
(16.95 § 1.44%) (Fig. 6D); DCX (8.24 § 1.29%)
(Fig. 6E); and glial marker GFAP (7.38 § 1.12%)
(Fig. 6F). Expression of other striatal neuronal
markers was also assessed, and co-expression was
seen with calbindin (1.62 § 0.77%) (Fig. 6G) and
parvalbumin (2.26 § 0.76%) (Fig. 6H). There was
no co-expression of b-Gal with DARPP32 (Fig. 6I)
or FoxP1 (Fig. 6J), with no expression of either
marker within the graft area and few immuno-
positive cells seen at the periphery of the graft
only.
Discussion
Forebrain-like character of FoxG1Z-derived
precursors
Serum-free neural induction suspension culture of
mouse ES cells resulted in generation of neural precur-
sor cells.9,11,15,27 Over time in culture, neurogenicity is
induced by default as demonstrated by upregulation
of the neuroectodermal marker Sox110,11 and the neu-
ral precursor marker Nestin,10 with a concurrent
down regulation of the ES cell marker Oct4.10,11,15 We
have previously shown a downregulation of the non-
neural markers Oct4, Nodal, Brachyury and Gooscoid
over time in the CDM culture system between day 0
and 8,15 with no expression of the muscle marker Des-
min or the epidermal marker pan-Cytokeratin.10,15
The cell line used in this study enabled analysis of
expression of the early forebrain marker FoxG1 via
use of the LacZ reporter gene.24 FoxG1Z ES cells
Figure 6. In vivo analysis of FoxG1Z-derived precursors. Photomicrographs of histological sections from brains transplanted with day 8
precursors (A) and day 16 precursors (B-J). Low magniﬁcation images of cresyl violet stained sections (A, B) show size and position of
the grafts. Higher magniﬁcation images reveal b-Gal immunoreactive cells present in the day 16-derived grafts (C), which allows for sub-
sequent analysis of FoxG1-positive cells. FoxG1-positive cells were shown to double-label with NeuN (D), DCX (E), GFAP (F), calbindin (G)
and parvalbumin (H). There was no double-labeling of FoxG1-positive cells with DARPP32 (I) or FoxP1 (J). Scale bars D 1 mm (A and B);
100 mm (C); 50 mm (D-J).
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cultured in CDM spontaneously formed aggregates,
grew as spheres and could be maintained under these
conditions for multiple days without the addition of
growth factors. When plated onto substrate, ﬁxed as
precursors without differentiation and stained with X-
Gal, blue cells were visualized. Using this assay we
showed an increase in FoxG1 positive cells over time
in culture as expected, up to 25% at 8 days, which was
higher than shown in a previous study.11 Watanabe
and colleagues showed that feeder-dependent cultures
maintained for 5 or 10 d resulted in less than 2%
FoxG1 positive cells; this was increased to 11% when
cultures were feeder-free and in suspension for the ini-
tial 5 days, and further increased to 15% when all 10 d
of culture were feeder-free and in suspension.11 The
CDM culture system used in this study appears to
encourage induction of FoxG1 precursors more than
other protocols,10,11 yielding higher proportions of
FoxG1 positive precursors, as determined using the
FoxG1Z ES cell line in combination with the X-Gal
assay. The extent to which these differences are due to
the different ES cell culture medium components is
currently uncertain.
Effect of addition of FGF2 and DKK1 on
FoxG1 expression
FGF2 signaling is important for the induction and
maintenance of normal mammalian telencephalic
development.28 In vivo studies have shown a relation-
ship between expression of Fgf8 and FoxG1, where
loss of FoxG1 results in reduced FGF8 expression in
the developing telencephalon.29 Neural plate explants
incubated with FGF8-soaked beads were shown to
extensively express FoxG1 in the area immediately
surrounding the beads as compared with PBS-soaked
beads, where no FoxG1 was expressed.26 Loss-of-func-
tion studies with Fgf8 mutant mice revealed that
FoxG1 expression was reduced in the neural plate (9-
10 somite stage) and also at the later gestational stage
E9.30
Addition of increasing concentrations of FGF2 to
FoxG1Z ES cells in neural induction cultures resulted
in an increase of FoxG1-expressing cells. This was
consistent with previous work that showed that treat-
ment at day 4 with 20ng/ml FGF2 (as presented here)
induced expression of FoxG1 at day 8.10 Previous
work showed that addition of FGF2 to mouse ES cells
undergoing neural induction within the CDM culture
system resulted in increased BrdU incorporation, with
a concomitant increase in expression of both Nestin
and FoxG1 at day 8.10,15 This increase in proliferating
cells with the increase in forebrain identity suggests
that FGF2 is affecting proliferation rather than lineage
selection. The lack of response to earlier FGF2 addi-
tion might be due to an absence of the appropriate
FGF receptors. FGFR1 is not detected in mouse ES
cells, but following initiation of neural induction it
can be detected at low levels from day 2 with increas-
ing expression through to day 8.15
During mouse development Wnt signaling is evi-
dent in the posterior region of the embryo from E6.5
and in EB development it is required for establishment
of the anterior-posterior axis.31 Inhibition of Wnt sig-
naling within EBs promotes anterior expression and
induces neuroectodermal differentiation.31 We did
not observe an effect of Wnt inhibition on FoxG1
expression in culture, neither when DKK1 was added
at day 4 at a range of concentrations nor when the
highest concentration (1000 ng/ml) was added on dif-
ferent starting days and maintained throughout. How-
ever, we did ﬁnd that the Wnt inhibitor DKK1 exerted
an effect on the Wnt signaling pathway within our
cultures, but it was not acting on the FoxG1 popula-
tion of cells. Our ﬁndings here are contradictory to a
previous study, which reported a signiﬁcant up-regu-
lation of FoxG1 expression following addition of
1000ng/ml DKK1 between days 0–5.11 In untreated
neural induction cultures Wnt3a has been shown to
be expressed from day 4 and its expression persists,
albeit at a reduced level, through to day 8.15 The same
cells were shown to endogenously express Dkk1 at day
4 through to day 8.15 Therefore, although the presence
of endogenous Wnt in neural induction cultures
might suggest a requirement for supplementation of
Wnt inhibitors to permit direction toward a neural
lineage (to anteriorise cultures), the concomitant pres-
ence of endogenous Dkk1 in these cultures might be
enough to inhibit alternative cell fates, without addi-
tion of exogenous Wnt inhibitors.
In vitro analysis of FoxG1Z-derived precursors
and neurons
Oct4 expression is exclusive to pluripotent cells.32 It is
expressed in ES cell lines derived from the inner cell
mass when cells are in an undifferentiated state and
when these cells begin to differentiate, expression of
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Oct4 rapidly down regulates. ES cells subjected to our
CDM protocol support this, and expression of Oct4
decreased over time in culture. Bouhon et al show
continued expression of Oct4 following 8 d in
CDM.10,15 Following a longer period in CDM culture
with continued FGF2 addition we demonstrated fur-
ther down-regulation of Oct4 and by day 16 Oct4 is
no longer expressed.
Expression of the neural precursor marker Nes-
tin in suspension culture of mouse ES cells in
CDM is signiﬁcantly decreased between day 8 and
day 16, which is consistent with a previous study
reporting a decrease in Nestin expression between
day 8 and day 12.15 Addition of FGF2 to serum-
free suspension cultures of ES cells has been shown
to maintain the proportion of Nestin-positive cells
over time in culture up to day 8, when compared
with CDM alone, and cultures older than day 8
depend on addition of exogenous FGF2 for sur-
vival.15 Analysis of Nestin-positive cells in neurally
induced cultures of ES cells prior to transplantation
revealed that the lower the proportion of Nestin-
positive cells, the lower the risk of teratoma forma-
tion in vivo.20
Assessment of dorso-ventral identity of cells in
CDM cultures revealed that neither Pax6 nor Nkx2.1
expression were signiﬁcantly different between cul-
tures at day 8 and day 16, but Mash1 expression was
signiﬁcantly higher in cultures at day 16 compared
with those at day 8. Data from other studies reveals
different expression patterns for these markers. Bou-
hon et al reported an increase in Pax6 expression at
day 8 compared with ES cells,10 and showed downre-
gulation of Pax6 expression following addition of
FGF2 and retinoic acid between day 4 and day 8 using
RT-PCR.15 Gaspard et al showed, an increase in
expression of Nkx2.1 from day 7 through to day 14,
using CDM culture without addition of any morpho-
gens.33 In a previous study from our group, a cDNA
expression array revealed an increase in expression of
Mash1 between ES cultures and day 8 CDM culture,
which was conﬁrmed by RT-PCR;15 expression
beyond day 8 was not analyzed. Taken together, these
data present an unclear picture of the dorso-ventral
expression pattern of ES cell-derived precursors over
time in culture. It further highlights the importance of
caution when interpreting results from studies using
differing cell culture media and differentiation condi-
tions, as well as different cell lines, and that reported
ﬁndings might be restricted to each individual culture
system.
FoxG1Z-derived precursors differentiated for 7 d in
neuronal differentiation medium, in the absence of
exogenous growth factors such as FGF, resulted in
generation of b-III-tubulin positive neurons with few
GFAP positive astrocytes. Here we demonstrate
between 30-40% b-III-tubulin positive cells as a per-
centage of total cells, which is comparable with other
studies, showing similar proportions of b-III-tubulin
neurons depending on the neural induction method
employed.19 The increase in GFAP expression
between cultures differentiated from day 8 and day 16
is consistent with previous work demonstrating a tem-
poral neurogenic-gliogenic switch following increased
time in neural induction culture.10
A proportion of the neurons generated were posi-
tive for GABA, the principle neurotransmitter of stria-
tal MSNs. The expression of b-III-tubulin and GABA
is consistent with previous in vitro differentiation
analysis of neurally induced mouse ES cells at the
same time points.10 Although we did not detect
expression of the striatal MSN marker DARPP32 in
neurons generated from day 8 cultures, a small pro-
portion of neurons generated from day 16 cultures did
express DARPP32. However, the proportion of both
GABA and DARPP32 positive neurons demonstrated
here are less than previously reported; where between
78-95% of b-III-tubulin neurons expressed GABA
and 32% of the GABAergic neurons expressed
DARPP32.19
In vivo analysis
Precise post-mortem analysis requires the ability to
distinguish between graft and host-derived cells fol-
lowing transplantation and in vivo differentiation. The
use of the FoxG1Z ES cell line in this study allowed
identiﬁcation of cells expressing LacZ and therefore
FoxG1. Only cells immunopositive for b-Gal were
positively identiﬁed as donor cells, and thus, due to
lack of another reliable marker, only these cells were
further characterized. It is therefore not straightfor-
ward to draw conclusions regarding the origin of sin-
gle-labeled cells, that is, whether graft or host derived.
Histological analysis revealed that all animals
within the day 8 group exhibited grafts with massive
overgrowth. The potential for ES cells to develop tera-
tomas following transplantation is one major downfall
NEUROGENESIS e1127311-9
in their consideration as an alternative cell source for
clinical applications. The appearance of non-neural-
like areas within the day 8 grafts together with the
overgrowth observed indicates the generation of tera-
tomas, which can be recognized by the presence of a
range of differentiated tissue types, representative of
the 3 germ layers.34 Encouraging observations reveal-
ing the potential of ES cell-derived precursors to gen-
erate desired phenotypes post-transplantation have
not been without undesirable differentiation.35-37
Indeed, within the same host brains, other ﬁndings
include undifferentiated ES cells, non-neural tissue
clusters,35 including epithelium, muscle and carti-
lage,36 and teratomas.37
In contrast, day 16 derived grafts displayed what
appeared to be healthy, surviving grafts at 6 weeks
post-transplantation, with no distortion of the brain
and no signs of over-growth. There was an indication
though that the grafts comprised heterogeneous cell
types of both neural and non-neural lineage. However,
this ﬁnding is not remarkable since non-neural differ-
entiation has previously been reported following neu-
ral transplantation, as detailed earlier.35-37
Graft volumes were variable within the day 16
graft group and looked comparable to volumes
from a previous study where mouse ES cell-derived
precursors were grafted into the adult rat QA-
lesioned striatum,16 although this study reported no
cell numbers or graft volumes. Primary rat striatal
tissue grafts, with similar cell numbers trans-
planted, generated a range of volumes 20 times
smaller than those reported here.38,39
Due to the problem of reliably identifying all donor
cells, further graft analysis considered only those cells
that were b-Gal positive. Grafted cells were shown to
generate both immature and more mature neurons,
shown by co-expression of b-Gal with the markers
DCX and NeuN, respectively, and also glial cells,
shown by co-expression with GFAP. Analysis of stria-
tal-speciﬁc neurons revealed expression of donor-
derived calbindin and parvalbumin, but neither
DARPP32 nor FoxP1. The presence of calbindin
immunopositive cells indicates striatonigral projection
neurons characteristic of the matrix compartment of
the striatum40 and parvalbumin immunoreactivity is
evidence of striatal medium aspiny neurons and inter-
neurons within the graft.
There are only a handful of reports on the survival
and phenotype of mouse ES cell-derived precursors
transplanted into the QA-lesioned striatum (reviewed
in ref. 6). Most recently, mouse ES cells underwent
neural induction using the monolayer method, were
transplanted into the QA-lesioned striatum at day 12
and a proportion of grafted cells were shown to
express DARPP32 at 4 weeks post-transplantation.19
However, there was some continued expression of
Oct4 at the time of transplantation and in some host
animals tumor formation was evident.
DARPP32 expression has been reported following
transplantation of human ES cell-derived neural pre-
cursors at both short and long-term survival times,
but only when the precursors themselves were ‘late’
stage following addition of BDNF, SHH and DKK1,
and not ‘early’ stage in vitro.21 Indeed, DARPP32 posi-
tive cells within the graft comprised 21% of the NeuN
population.21 Human ES cells cultured in FGF2 and
Noggin for 4 weeks prior to engraftment into unle-
sioned rat striata generated 30% DARPP32 positive
neurons at 6 months post-transplantation, (expressed
as a percentage of Human Nuclei immunopositive
cells),41 and human ES cell-derived precursors trans-
planted into the QA-lesioned striatum at 40 d follow-
ing addition of SHH with subsequent exposure to
valproic acid generated more than 50% DARPP32
positive cells, as a percentage of total grafted cells.22 A
dual SMAD inhibtion approach with subsequent
modulation of SHH and Wnt pathways resulted in
generation of a population DARRP32-expressing cells
with concomitant reduction in apomorphine-induces
rotations compared with non-grafted animals.23 How-
ever, these studies also reported signiﬁcant graft over-
growth;21,22 with 35 fold expansion of grafted cells
over the 4 month post-transplantation period.22 Most
recently, addition of Activin A has been shown to
induce expression of markers of the lateral ganglionic
eminence with 20-50% DARPP32 immunopositive
neurons in vitro.42 Following transplantation into the
rat QA-lesioned striatum this protocol yielded high
levels of DARPP32-expressing cells at 16 weeks post-
transplant (50% of all Human Nuclei immunopositive
cells), and, encouragingly, no sign of graft
overgrowth.42
The precursors used in this study are likely too
immature in terms of their gene expression proﬁle
and it is possible that precursors that have undergone
additional patterning to further specify their fate
would be more disposed to generation of DARPP32.
Interestingly, Nasonkin et al reported no DARPP32
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positive cells at 3 months post-transplantation but at 6
months DARPP32 was detected, suggesting that
increased time in vivomay also play a part in inducing
grafted cells to differentiate toward the DARPP32
phenotype.41 This mirrors what has been reported fol-
lowing transplantation of primary human fetal striatal
tissue into the rat QA-lesioned striatum, and further
emphasizes the need for transplantation models that
will allow for long-term assessment of grafts.43 The
absence of DARPP32 within the grafts presented here
is most likely due to a combination of the aforemen-
tioned issues; cells were not exposed to all the neces-
sary differential cues while in culture prior to
transplantation, and also the in vivo maturation
period was not long enough to encourage induction of
more mature neuronal phenotypes such as DARPP32.
Conclusions
Using suspension cultures of ES cells we highlight the
importance of concentration and timing of exposure
to factors to endeavor to direct the fate of these cells.
We show that increased time in induction culture
down-regulates expression of stem cell markers, which
results in reduced potential for teratoma formation.
However, it is understandable that a combination of
factors will be needed in order to generate striatal-like
progenitor cells. Together, this demonstrates the need
for further controlled reﬁnement of protocols both in
vitro and in vivo, to achieve the desired striatal pheno-
type population.
Materials and methods
Cell culture
The mouse ES cell line FoxG1-LacZ (FoxG1Z),
derived from FoxG1lacZ mice24 was used (a gift from J.
Quinn and D. Price, University of Edinburgh). ES cells
were maintained in feeder-free culture conditions in
Iscove’s Modiﬁed Dulbecco’s Medium supplemented
with 15% knock-out serum replacement, 1% penicil-
lin/streptomycin (PS), 1mM non-essential amino
acids, 2mM L-glutamine (all Gibco, Paisley, Scotland,
UK), 0.1mM b-mercaptoethanol (Sigma, Gillingham,
Dorset, UK) and leukemia inhibitory factor (LIF)
(produced ‘in-house’).
For neural induction, ES cells were enzymatically
harvested with trypsin-EDTA (Gibco) and resus-
pended at a density of 5 £ 105 cells/ml on
bacteriological-grade culture dishes (Sterilin, Newport,
UK) in CDM: Advanced DMEM/F12 supplemented
with 1 £ lipid concentrate, 1% PS, 2mM L-glutamine
(all Gibco), transferrin (ﬁnal concentration 150 mg/
ml), insulin (ﬁnal concentration 14 mg/ml) (both
Sigma) and 0.1mM b-mercaptoethanol. The day of
transfer to CDM was day 0 and medium was changed
every 2 d FGF2 and DKK1 (both R&D Systems,
Oxfordshire, UK) were used at 20ng/ml and 1000ng/
ml, respectively, unless otherwise stated.
For neuronal differentiation of neurally induced
cells, cells were harvested and incubated in accutase
(PAA Laboratories, Somerset, UK) at 37C for 15 min.
A single-cell suspension was generated by trituration
and cells were plated at a density of 25,000cells/cm2 in
neuronal differentiation medium (DMEM/F-12, 1%
PS, 2% B-27 and 1% FCS) on poly-L-lysine (PLL)-lami-
nin-coated coverslips.
X-Gal assay
The presence of b-Gal activity in cultures was detected
by plating cells onto PLL-laminin-coated coverslips,
partially ﬁxing in 4% formaldehyde for 10 min fol-
lowed by incubation in 1 mg/ml 5-bromo-4-chloro-3-
indolyl galactopyranoside (X-Gal) (Fermentas, Ther-
moScientiﬁc). Cells were counter-stained with eosin.
Fluorescent immunocytochemistry
Cells were plated and ﬁxed after 4 hours (as precur-
sors) or 7 d (as differentiated cells), in 4% formalde-
hyde or 0.2% glutaraldehyde in 4% formaldehyde.
Fluorescent immunocytochemistry was performed
using standard protocols using the following primary
antibodies: anti-b-Gal (1:1000, Promega), anti-Nestin
(1:400, BD Pharm), anti-Oct4 (1:100, Santa Cruz),
anti-Pax6 (1:50, DSHB), anti-Nkx2.1 (1:100, DAKO),
anti-Mash1 (1:200, BDPharm), anti-b-III-tubulin
(mouse 1:1000; rabbit 1:500, both Sigma), anti-GFAP
(1:2000, DAKO), anti-GABA (1:500, Sigma), anti-
DARPP32 (1:20,000, a gift from Paul Greengard) and
anti-FoxP1 (1:500, Abcam). Secondary antibodies
used were Alexa-ﬂuor a 594 anti-mouse and a 488
anti-rabbit (both 1:200, DAKO).
Cells were visualised under UV ﬂuorescence using a
Leitz microscope and cell counts were performed
using a grid randomly placed over 5 different ﬁelds
per coverslip. The number of positive cells counted
was expressed as mean § SEM from replicates of 3–4
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coverslips per condition. Images were processed using
Optronics MagnaFire Software and Adobe Photoshop.
Transplantation experiments
All animal experiments were conducted in compliance
with local ethical guidelines and approved animal care
according to the UK Animals (Scientiﬁc Procedures)
Act 1986 and its subsequent amendments.
Adult female Sprague-Dawley rats (Harlan, UK)
received unilateral injections of 45nmol QA into the
right striatum, as described previously.44
Cells were harvested on day 8 and day 16 of CDM
culture and a single-cell suspension was generated
using accutase (described above). Cells were grafted at:
C0.6 mm AP, ¡2.8 mm ML and ¡5.0 and ¡4.0 mm
below dura; 250,000 cells/ml at 1ml/min, 1 min at each
of 2 heights. The needle was left at the graft site for a
further 2 min before withdrawal. From the day prior to
grafting and for the duration of the experiment, ani-
mals received daily immunosuppression; cyclosporin A
(10 mg/kg; intraperitoneal) (Sandimmun, Novartis,
Hampshire, UK). Post-operatively animals were admin-
istered 5ml 4% glucose/saline solution and analgesia in
the form of Metacam (both subcutaneous).
Immunohistochemistry
Rats were transcardially perfused and tissue was pre-
pared, as previously described.44 Sections were proc-
essed for Nissl staining using cresyl violet and
immunohistochemistry with the following antibodies:
anti-b-Gal (1:1000, Promega), anti-GFAP (1:2000,
DAKO), anti-NeuN (1:4000, Chemicon), anti-double-
cortin (DCX, 1:500, Abcam), anti-DARPP32
(1:10,000, a gift from Paul Greengard), anti-FoxP1
(1:500, Abcam), anti-calbindin (1:20,000, Sigma) and
anti-parvalbumin (1:4000, Sigma). The basic protocol
was the same for each antibody.
Quantiﬁcation and statistical analysis
Graft volumes were determined based on b-Gal
immuno-reactivity. Cells expressing markers of inter-
est were counted at 100x magniﬁcation using a Leitz
light microscope and stereology software (Olympus
CASTgrid stereology).
Statistical signiﬁcance was assessed by t-test and
ANOVA with post-hoc Tukey-Kramer (Minitab 15
statistical software).
Abbreviations
b-Gal b-galactosidase
CDM chemically deﬁned medium
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galactopyranosideneuron
Disclosure of potential conﬂicts of interest
No potential conﬂicts of interest were disclosed.
Funding
This work was supported by grants from the Medical Research
Council (MRC) UK. SVP was supported by a studentship from
the MRC UK.
Author contributions
SVP was involved in study design, carried out cell culture and
surgical procedures, collected all data, performed data analysis
and drafted the manuscript. CMK was involved in study
design, carried out surgical procedures and critically revised
the manuscript. NDA was involved in the concept and study
design. AER was involved in study design and critically revised
the manuscript. All authors approved the ﬁnal manuscript for
publication.
References
[1] Dunnett SB, Rosser AE. Cell therapy in Huntington’s dis-
ease. NeuroRx 2004; 1:394–405; PMID:15717043; http://
dx.doi.org/10.1602/neurorx.1.4.394
[2] Rosser AE, Kelly CM, Dunnett SB. Cell transplantation
for Huntington’s disease: Practical and clinical consider-
sations. Future Neurol 2011; 6:45–62; http://dx.doi.org/
10.2217/fnl.10.78
[3] Kelly CM, Dunnett SB, Rosser AE. Medium spiny neu-
rons for transplantation in Huntington’s disease. Bio-
chem Soc Trans 2009; 37:323–28; PMID:19143656;
http://dx.doi.org/10.1042/BST0370323
[4] Evans MJ, Kaufman MH. Establishment in culture of
pluripotential cells from mouse embryos. Nature 1981;
292:154–56; PMID:7242681; http://dx.doi.org/10.1038/
292154a0
[5] Martin GR. Isolation of a pluripotent cell line from early
mouse embryos cultured in medium conditioned by
teratocarcinoma stem cells. Proc Natl Acad Sci USA
1981; 78:7634–38; PMID:6950406; http://dx.doi.org/
10.1073/pnas.78.12.7634
e1127311-12 S. V. PRECIOUS ET AL.
[6] Precious SV, Rosser AE. Producing striatal phenotypes
for transplantation in Huntington’s disease. Exp Biol
Med 2012; 237:343–51; http://dx.doi.org/10.1258/ebm.
2011.011359
[7] Bain G, Kitchens D, Yao M, Huettner JE, Gottlieb DI.
Embryonic stem cells express neuronal properties in
vitro. Dev Biol 1995; 168:342–57; PMID:7729574; http://
dx.doi.org/10.1006/dbio.1995.1085
[8] Okabe S, Forsbergnilsson K, Spiro AC, Segal M, McKay
RD. Development of neuronal precursor cells and func-
tional postmitotic neurons from embryonic stem cells in
vitro. Mech Dev 1996; 59:89–102; PMID:8892235; http://
dx.doi.org/10.1016/0925-4773(96)00572-2
[9] Ying QL, Stavridis M, Grifﬁths D, Li M, Smith A. Con-
version of embryonic stem cells into neuroectodermal
precursors in adherent monoculture. Nat Biotechnol
2003; 21:183–86; PMID:12524553; http://dx.doi.org/
10.1038/nbt780
[10] Bouhon IA, Joannides A, Kato H, Chandran S, Allen ND.
Embryonic stem cell-derived neural progenitors display
temporal restriction to neural patterning. Stem Cells
2006; 24:1908–13; PMID:16627686; http://dx.doi.org/
10.1634/stemcells.2006-0031
[11] Watanabe K, Kamiya D, Nishiyama A, Katayama T,
Nozaki S, Kawasaki H, Watanabe Y, Mizuseki K, Sasai Y.
Directed differentiation of telencephalic precursors from
embryonic stem cells. Nat Neurosci 2005; 8:288–96;
PMID:15696161; http://dx.doi.org/10.1038/nn1402
[12] Smukler SR, Runciman SB, Xu S, van der Kooy D.
Embryonic stem cells assume a primitive neural stem cell
fate in the absence of extrinsic inﬂuences. J Cell Biol
2006; 172:79–90; PMID:16390999; http://dx.doi.org/
10.1083/jcb.200508085
[13] Gulacsi AA, Anderson SA. Beta-catenin-mediated Wnt
signaling regulatesneurogenesis in the ventral telencepha-
lon. Nat Neurosci 2008; 11:1383–91; PMID:18997789;
http://dx.doi.org/10.1038/nn.2226
[14] Bain G, Ray WJ, Yao M, Gottlieb DI. Retinoic acid pro-
motes neural and represses mesodermal gene expression
in mouse embryonic stem cells in culture. Biochem Bio-
phys Res Comm 1996; 223:691–94.
[15] Bouhon IA, Kato H, Chandran S, Allen ND. Neural dif-
ferentiation of mouse embryonic stem cells in chemically
deﬁned medium. Brain Res Bull 2005; 68:62–75;
PMID:8687458; PMID:16325006; PMID:8689027; http://
dx.doi.org/10.1016/j.brainresbull.2005.08.022
[16] Dinsmore J, Ratliff J, Deacon T, Pakzaban P, Jacoby D,
Galpern W, Isacson O. Embryonic stem cells differenti-
ated in vitro as a novel source of cells for transplantation.
Cell Transplant 1996; 5:131–43.; http://dx.doi.org/
10.1016/0963-6897(95)02040-3
[17] Bernreuther C, Dihne M, Johann V, Schiefer J, Cui Y, Hargus
G, Schmid JS, Xu J, Kosinski CM, Schachner M. Neural cell
adhesion molecule L1-transfected embryonic stem cells pro-
mote functional recovery after excitotoxic lesion of the mouse
striatum. J Neurosci 2006; 26:11532–39; PMID:17093074;
http://dx.doi.org/10.1523/JNEUROSCI.2688-06.2006
[18] Hargus G, Cui Y, Schmid JS, Xu J, Glatzel M, Schachner M,
Bernreuther C. Tenascin-R promotes neuronal differentiation
of embryonic stem cells and recruitment of host-derived neu-
ral precursor cells after excitotoxic lesion of the mouse stria-
tum. StemCells 2008; 26:1973–84; PMID:18499893; http://dx.
doi.org/10.1634/stemcells.2007-0929
[19] Shin E, Palmer MJ, Li M, Fricker RA. GABAergic neu-
rons from mouse embryonic stem cells possess functional
properties of striatal neurons in vitro, and develop into
striatal neurons in vivo in a mouse model of Hunting-
ton’s disease. Stem Cell Rev 2012; 8(2):513–31;
PMID:21720791; http://dx.doi.org/10.1007/s12015-011-
9290-2
[20] Dihne M, Bernreuther C, Hagel C, Wesche KO, Schach-
ner M. Embryonic stem cell-derived neuronally commit-
ted precursor cells with reduced teratoma formation after
transplantation into the lesioned adult mouse brain.
Stem Cells 2006; 24:1458–66; PMID:16456136; http://dx.
doi.org/10.1634/stemcells.2005-0413
[21] Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M,
Perrier AL. Striatal progenitors derived from human ES
cells mature into DARPP32 neurons in vitro and in qui-
nolinic acid-lesioned rats. Proc Natl Acad Sci USA 2008;
105:16707–12; PMID:18922775; http://dx.doi.org/
10.1073/pnas.0808488105
[22] Ma L, Hu B, Liu Y, Vermilyea SC, Liu H, Gao L, Sun Y,
Zhang X, Zhang SC. Human Embryonic Stem Cell-
Derived GABA Neurons Correct Locomotion Deﬁcits in
Quinolinic Acid-Lesioned Mice. Cell Stem Cell 2012;
10:455–64; PMID:22424902; http://dx.doi.org/10.1016/j.
stem.2012.01.021
[23] Delli-Carri A, Onorati M, Lelos MJ, Castiglioni V, Faedo
A, Menon R, Camnasio S, Vuono R, Spaiardi P, Talpo F,
et al. Developmentally coordinated extrinsic signals drive
human pluripotent stem cell differentiation toward
authentic DARPP-32C medium-sized spiny neurons.
Development 2013; 140:301–12; PMID:23250204; http://
dx.doi.org/10.1242/dev.084608
[24] Xuan S, Baptista CA, Balas G, Tao W, Soares VC, Lai E.
Winged helix transcription factor BF-1 is essential for the
development of the cerebral hemispheres. Neuron 1995;
14:1141–52; PMID:7605629; http://dx.doi.org/10.1016/
0896-6273(95)90262-7
[25] Tao W, Lai E. Telencephalon-restricted expression of BF-
1, a new member of the HNF-3/fork head gene family, in
the developing rat brain. Neuron 1992; 8:957–66;
PMID:1350202; http://dx.doi.org/10.1016/0896-6273(92)
90210-5
[26] Shimamura K, Rubenstein JL. Inductive interactions
direct early regionalization of the mouse forebrain.
Development 1997; 124:2709–18; PMID:9226442
[27] Wiles MV, Johansson BM. Embryonic stem cell develop-
ment in a chemically deﬁned medium. Exp Cell Res
1999; 247:241–48; PMID:10047466; http://dx.doi.org/
10.1006/excr.1998.4353
[28] Paek H, Gutin G, Hebert JM. FGF signaling is strictly
required to maintain early telencephalic precursor cell
NEUROGENESIS e1127311-13
survival. Development 2009; 136:2457–65;
PMID:19542358; http://dx.doi.org/10.1242/dev.032656
[29] Martynoga B, Morrison H, Price DJ, Mason JO. FoxG1 is
required for speciﬁcation of ventral telencephalon and
region-speciﬁc regulation of dorsal telencephalic precur-
sor proliferation and apoptosis. Dev Biol 2005; 283:113–
27; PMID:15893304; http://dx.doi.org/10.1016/j.ydbio.
2005.04.005
[30] Storm EE, Garel S, Borello U, Hebert JM, Martinez S,
McConnell SK, Martin GR, Rubenstein JL. Dose-depen-
dent functions of Fgf8 in regulating telencephalic pat-
terning centers. Development 2006; 133:1831–44;
PMID:16613831; http://dx.doi.org/10.1242/dev.02324
[31] ten Berge D, Koole W, Fuerer C, Fish M, Eroglu E,
Nusse R. Wnt signaling mediates self-organization and
axis formation in embryoid bodies. Cell Stem Cell 2008;
3:508–18; PMID:18983966; http://dx.doi.org/10.1016/j.
stem.2008.09.013
[32] Niwa H, Miyazaki J, Smith AG. Quantitative expression
of Oct-3/4 deﬁnes differentiation, dedifferentiation or
self-renewal of ES cells. Nat Genet 2000; 24:372–76;
PMID:10742100; http://dx.doi.org/10.1038/74199
[33] Gaspard N, Bouschet T, Hourez R, Dimidschstein J,
Naeije G, van den AJ, Espuny-Camacho I, Herpoel A,
Passante L, Schiffmann SN, Gaillard A, Vanderhaeghen
P. An intrinsic mechanism of corticogenesis from embry-
onic stem cells. Nature 2008; 455:351–57;
PMID:18716623; http://dx.doi.org/10.1038/nature07287
[34] Przyborski SA. Differentiation of human embryonic stem
cells after transplantation in immune-deﬁcient mice.
Stem Cells 2005; 23:1242–50; PMID:16210408; http://dx.
doi.org/10.1634/stemcells.2005-0014
[35] Br€ustle O, Spiro AC, Karram K, Choudhary K, Okabe S,
McKay RD. In vitro-generated neural precursors partici-
pate in mammalian brain development. Proc Natl Acad
Sci USA 1997; 94:14809–14; PMID:9405695; http://dx.
doi.org/10.1073/pnas.94.26.14809
[36] Benninger Y, Marino S, Hardegger R, Weissmann C, Aguzzi
A, Brandner S. Differentiation and histological analysis of
embryonic stem cell-derived neural transplants in mice. Brain
pathol 2000; 10:330–41; PMID:10885652; http://dx.doi.org/
10.1111/j.1750-3639.2000.tb00265.x
[37] Wernig M, Benninger F, Schmandt T, Rade M, Tucker
KL, B€ussow H, Beck H, Br€ustle O. Functional integration
of embryonic stem cell-derived neurons in vivo. J Neuro-
sci 2004; 24:5258–68; PMID:15175396; http://dx.doi.org/
10.1523/JNEUROSCI.0428-04.200
[38] Pakzaban P, Deacon TW, Burns LH, Isacson O.
Increased proportion of acetylcholinesterase-rich
zones and improved morphological integration in
host striatum of fetal grafts derived from the lateral
but not the medial ganglionic eminence. Exp Brain
Res 1993; 97:13–22; PMID:7907548; http://dx.doi.org/
10.1007/BF00228813
[39] Olsson M, Campbell K, Wictorin K, Bj€orklund A. Projec-
tion neurons in fetal striatal transplants are predomi-
nantly derived from the lateral ganglionic eminence.
Neurosci 1995; 69:1169–82; http://dx.doi.org/10.1016/
0306-4522(95)00325-D
[40] Gerfen CR. The neostriatal mosaic: multiple levels of
compartmental organization. Trends Neurosci 1992;
15:133–39; PMID:1374971; http://dx.doi.org/10.1016/
0166-2236(92)90355-C
[41] Nasonkin I, Mahairaki V, Xu L, Hatﬁeld G, Cummings
BJ, Eberhart C, Ryugo DK, Maric D, Bar E, Koliatsos
VE. Long-term, stable differentiation of human embry-
onic stem cell-derived neural precursors grafted into
the adult mammalian neostriatum. Stem Cells 2009;
27:2414–26; PMID:19609935; http://dx.doi.org/
10.1002/stem.177
[42] Arber C, Precious SV, Cambray S, Risner-Janiczek JR,
Kelly C, Noakes Z, Fjodorova M, Heuer A, Ungless MA,
Rodriguez TA, Rosser AE, Dunnett SB, Li M. Activin A
directs striatal projection neuron differentiation of
human pluripotent stem cells. Development 2015;
142:1375–86; PMID:25804741; http://dx.doi.org/10.1242/
dev.117093
[43] Kelly CM, Precious SV, Scherf C, Penketh RJ, Amso
NN, Battersby A, Allen ND, Dunnett SB, Rosser AE.
Neonatal desensitization allows long-term survival of
neural xenotransplants without immunosuppression.
Nat Meth 2009; 6:271–73; http://dx.doi.org/10.1038/
nmeth.1308
[44] Kelly CM, Precious SV, Penketh RJ, Amso N, Dunnett
SB, Rosser AE. Striatal graft projections are inﬂuenced by
donor cell type and not the immunogenic background.
Brain 2007; 130:1317–29; PMID:17395612; http://dx.doi.
org/10.1093/brain/awm053
e1127311-14 S. V. PRECIOUS ET AL.
